A Phase 3 interventional study of THC/CBD and THC in Back Pain and Neck Pain, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 21 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by University of Colorado, Denver · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 307 studies in Back Pain with a site in United States — 38 open to participants now, 51 under way, 4 of them phase 3. Back Pain · United States.
Among the 307 studies in Back Pain with a site in United States, this one is the 81st largest by planned enrollment of the 262 interventional ones that give a count, is one of 10 that started in 2026, is one of 30 in phase 3, reaches primary completion later than 30 of the 50 other live ones, and was the 233rd registered.
729 studies on the registry are indexed under Back Pain; 110 are open to participants now.
Browse Back Pain studies →38 of the 307 studies in Back Pain with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
University of Houston · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Northwestern University · Sites in United States, Thailand, Ukraine
University of Colorado, Denver · Sites in United States
Ages 18+
Consano Bio · Sites in United States, Australia
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.
This study: 21 Years to 84 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
307 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 29 · Phase 3 33 · Phase 4 30
First in 1997; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 157 is above the median of 70 across 594 interventional studies indexed under Back Pain.
Median enrollment 76 across the 262 interventional studies, 133 across the 44 observational. Of the 228 that completed or were terminated, 105 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 307 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
University of Colorado, Denver has 4 studies filed under Back Pain — fewer than ten, so there is no comparison to draw.
21 of the studies in Back Pain with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058287Phase 3Hospital for Special Surgery, New YorkLumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression | 2026-12-31 |
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT05052541Phase 3University of Colorado, DenverSafety and Efficacy of Oral Cannabis in Chronic Spine Pain | 2027-06 |
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT06007976Mayo ClinicLLLT to Reduce Low Back Pain | 2026-12 |
Add all 21 to your calendar (.ics) → With an account.
Among the 307 studies in Back Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objectives of this study are to investigate the efficacy of extended cannabis treatment to reduce patient exposure to prescription opioids through its use 1) as a non-opioid analgesic treatment, and 2) as a therapy for reducing high-dose opioid use in patients with chronic spine pain.
This randomized, placebo-controlled clinical trial is designed to elucidate the role of extended oral cannabis treatment in the alleviation of chronic spine pain and reduction of high-dose opioid use. This trial includes two study arms: Analgesia Arm and Reduction Arm. The Analgesia Arm uses a within-subject crossover design to determine whether daily treatment with an oral cannabis solution for 6 weeks significantly reduces spine pain compared to placebo. The Reduction Arm uses a parallel design to determine whether daily treatment with an oral cannabis solution for 13 weeks results in a greater reduction of pain and opioid intake than placebo treatment. It will also assess the impact of extended cannabis treatment on opioid craving and symptoms of opioid withdrawal in participants tapering their high-dose opioids.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Some inclusion/exclusion criteria are purposely omitted at this time to preserve scientific integrity. They will be included after the trial is complete.
Inclusion Criteria:
Self-reported chronic (≥3 months' duration), non-radicular spine pain
Exclusion Criteria:
Unwilling/unable to refrain from cannabis use (medical or recreational) for 14 days prior to Baseline Visit and throughout the study (other than study drug). This includes whole plant inhalation, edibles, extracts, and topicals.
Co-morbid cancer-related pain condition
Neuropathic Pain
A co-morbid pain condition that is of greater severity than the patient's spine pain
Spine or other major surgery within the 3 months prior to enrollment
Planned surgery or procedural intervention during the study period
Allergy or adverse reaction to cannabis
Current or historical substance use disorder
Current or historical alcohol use disorder
Current or prior cannabis abuse/dependence
Positive result for use of amphetamine/methamphetamine, barbiturates, benzodiazepines, cocaine, phencyclidine (PCP), ecstasy (MDMA), as detected on urine screen
Current use of valproate, clobazam, clopidogrel, warfarin, barbiturates, benzodiazepines
Prior adverse reaction to cannabis exposure (paranoia, anxiety, etc.)
History or diagnosis of schizophrenia, bipolar or a psychotic disorder
History of any mental health illness that in the opinion of the Investigator would compromise the safety of the participant
Current or historical severe depression
Current suicidal ideation
Diagnosed cognitive impairment (e.g. Alzheimer's Disease, traumatic brain injury)
Uncontrolled hypertension (>139/89)
Abnormal values on CBC (complete blood count) or CMP (comprehensive metabolic panel) laboratory analysis that are deemed by study physician
Known hepatic disease or dysfunction, or identification of such on screening laboratory studies
Known cardiovascular disease
Abnormal result on (ECG) that is deemed clinically significant by study MD
Cognitive disability that interferes with ability to provide consent or understand study procedure
History of seizure disorder
Any medical condition for which therapy is required.
Inability to refrain from using tobacco for at least 4 hours
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data
Pending legal action or workers compensation
Pregnant females or females intending to become pregnant during the study period
Unwilling to use one of the accepted forms of during the study period and for at least 60 days after completion of the study (females of and males with sexual partners of childbearing potential)
Lactating females
Analgesia Arm Exclusion Criteria:
Unwilling/unable to discontinue current opioid use for 14 days prior to Baseline study visit and throughout the study
Reduction Arm Exclusion Criteria:
Not interested in reducing or discontinuing use of prescribed opioids for chronic pain
Unwilling to allow the study team to communicate with the participant's opioid prescribing provider
*Some inclusion/exclusion criteria are purposely omitted at this time to preserve scientific integrity. They will be included after the trial is complete.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
Drug: THC/CBD · Drug: THC · Drug: Placebo
Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
Drug: THC/CBD · Drug: THC · Drug: Placebo
Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
Drug: THC/CBD · Drug: THC · Drug: Placebo
Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
Drug: THC/CBD · Drug: THC · Drug: Placebo
Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
Drug: THC/CBD · Drug: THC · Drug: Placebo
Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
Drug: THC/CBD · Drug: THC · Drug: Placebo
Subjects in this parallel arm will be assigned to 13 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
Drug: THC/CBD
Subjects in this parallel arm will be assigned to 13 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
Drug: Placebo
Drug pages: DronabinolStudies of DronabinolDronabinol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CannabidiolStudies of CannabidiolCannabidiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Oral solution containing 5mg THC and 50 mg CBD per 1 ml
Oral solution containing 5mg THC per 1 ml
Oral solution containing no active drug
Change in chronic pain as measured by the Visual Analog Scale (VAS) for pain
The Visual Analog Scale (VAS) for pain is a 0-100mm visual scale anchored by "no pain" and "worst possible pain".
Time frame: Weekly, up to week 22
Change in opioid dose as measured in morphine milligram equivalents (MME)
Time frame: Weekly, up to week 22
Study Drug Tolerability as measured by study drug use
study drug dose, frequency
Time frame: Daily, up to week 22
Study Drug Tolerability as measured by side effects
Time frame: Daily, up to week 22
Change in spine-related disability and quality of life as measured on the NIH Patient Reported Outcomes Measurement System (PROMIS)-29
The NIH Patient Reported Outcomes Measurement System (PROMIS)-29 is a collection of 4-item short forms assessing anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, and ability to participate in social roles and activities as well as a single pain intensity item.
Time frame: Weekly, up to week 22
Change in spine-related disability and quality of life as measured on the NIH Task Force on Research Standards for Chronic Low-Back/Neck Pain Minimal Dataset
The NIH Task Force on Research Standards for Chronic Low-Back Pain Minimal Dataset (and the modified Dataset for neck pain) assesses the influence of back/neck pain on physical function, emotional health, sleep, everyday activities.
Time frame: Weekly, up to week 22
Change in use of opioid and non-opioid analgesic medications
Time frame: Daily, up to week 22
Change in abuse liability of cannabis as measured on the Drug Effects Questionnaire (DEQ) for study drug (cannabis)
The Drug Effects Questionnaire (DEQ) for study drug (cannabis) assesses the subjective effects after taking a drugs, including feeling a drug effect, liking/disliking the drug effect, feeling high, and wanting more drug.
Time frame: Weekly, up to week 22
Change in abuse liability of cannabis as measured on a VAS for study drug (cannabis) craving
The VAS for study drug (cannabis) craving is a 100 mm visual scale anchored by "not at all" and "extremely" when asked about drug craving in the past week
Time frame: Weekly, up to week 22
Change in opioid craving and withdrawal as measured on a VAS for opioid craving
The VAS for opioid craving is a 100 mm visual scale anchored by "not at all" and "extremely" when asked about opioid craving in the past week.
Time frame: Weekly, up to week 22
Change in opioid craving and withdrawal as measured on the Subjective Opiate Withdrawal Scale (SOWS)
The Subjective Opiate Withdrawal Scale (SOWS) is a self-report questionnaire containing 16 symptoms related to opioid withdrawal.
Time frame: Weekly, up to week 22
Change in opioid craving and withdrawal as measured on the Drug Effect Questionnaire (DEQ)
The Drug Effects Questionnaire (DEQ) for opioids assesses the subjective effects after taking opioids, including feeling a drug effect, liking/disliking the drug effect, feeling high, and wanting more opioids.
Time frame: Weekly, up to week 22
Change in opioid craving and withdrawal as measured on the Current Opioid Misuse Measure (COMM).
Current Opioid Misuse Measure (COMM) is a brief patient self-assessment to help identify participants who exhibit aberrant behaviors associated with the misuse of opioid medications.
Time frame: Weekly, up to week 22
Change in pain sensitivity as measured by pain threshold (kPa) to a pressure stimulus
Pressure output on a computer-controlled pressure algometer will be set to 10 kPa/s and participants will be instructed to indicate when the sensation changes from one of pressure alone to one of pressure and pain (pain threshold) by pressing a button on the remote-control indicator
Time frame: Weekly, up to week 22
Change in cognition as assessed by the List Sorting Working Memory Test
The List Sorting Working Memory Test measures attention/working memory. Participants recall and sequence different visually and orally presented stimuli (e.g., participants are asked to list a set of given animals in order by size, from smallest to largest).
Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in cognition as assessed by the Pattern Comparison Processing Speed Test
The Pattern Comparison Processing Speed Test is a measure of processing speed. Participants discern whether two side-by-side pictures are the same or not, with 85 seconds to respond to as many items as possible.
Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in cognition as assessed by the Oral Symbol Digit Test
The Oral Symbol Digit Test is a measure of processing speed. Symbols on the screen are associated with a number in a key. Participants are then presented symbols without numbers. Participants say each number that goes with each presented symbol for 90 seconds.
Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in cognition as assessed by the Flanker Inhibitory Control and Attention Test
The Flanker Inhibitory Control and Attention Test measures attention and inhibitory control. Participants are required to indicate the left-right orientation of a centrally presented stimulus while inhibiting attention to the potentially incongruent stimuli that surround it (i.e., the flankers, two on either side).
Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in cognition as assessed by the Picture Vocabulary Test
The Picture Vocabulary Test measures receptive vocabulary. Respondents select pictures (from arrays) that most closely match the meanings of presented words.
Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in cognition and motor skills as assessed by the Hopkins Verbal Learning Test Revised (HVLT-R)
The HVLT-R is a measure of verbal learning and memory. Participants are asked to learn a 12-item word list over three trials (total immediate learning). A delayed free recall trial is administered after 20 minutes, followed by a yes/no recognition trial.
Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in motor skills as assessed by the Grooved Pegboard Test
The Grooved Pegboard is a test of fine motor coordination and speed. In this test, participants place 25 small metal pegs into holes on a 3"x3" metal board as quickly as possible. All pegs are alike and have a ridge on 1 side that corresponds to a randomly oriented notch in each hole on the metal board.
Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in motor skills as assessed by the Standardized Field Sobriety Test
The Standardized Field Sobriety Test is intended to detect driving impairments due to recent alcohol or drug use.
Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in participant's perceived improvement in spine pain as measured on the Patient Global Impression of Change Scale (PGIC)
The Patient Global Impression of Change Scale (PGIC) is a 7-point scale depicting a patient's rating of overall improvement.
Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in 2-arachidonoylglycerol levels as measured in plasma
2-arachidonoylglycerol will be measured in pmol/ml
Time frame: Baseline, Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in N-arachidonoylethanolamine levels as measured in plasma
N-arachidonoylethanolamine will be measured in pmol/ml
Time frame: Baseline, Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in tumor necrosis factor alpha (TNF-α) levels as measured in plasma
TNF-α will be measured in pg/ml
Time frame: Baseline, Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Change in C-reactive protein (CRP) levels as measured in plasma
CRP will be measured in mg/L
Time frame: Baseline, Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)
Start is estimated for Jan 2026; primary completion for Jun 2027, 17 months later.
Of 16 phase 3 interventional studies under Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 62. This study's planned 17 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dronabinol · Cannabidiol
University of Colorado, Denver →